MYP_153938
Durvalumab
Anticancer
Immunology
▸
Immune modulation
▸
Immunomodulatory activity
Immunology
▸
Immunomodulation
▸
Immuno-oncology
Standard
451 amino acids
C2212H3409N589O677S16
Standard
EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEFEGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPASIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
49598.31 Da
8.20
3.55
2.63
0.0079
-0.42
0.72
0.01
47.04
68.40
0.0998
83310.00
83935.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Amino Acid Composition
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
RECORD: Rec_0344550
VERIFIED: NO
Provenance & Taxonomy
Homo sapiens [Animal]; Mus musculus [Animal]
Monoclonal antibody
9606;10090
Structure & Mods
linear peptide/protein therapeutic [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Anticancer
Immunomodulatory
Immuno-oncology
Based on baseline clearance rate, the geometric mean terminal half-life is 18 days.[L12621,L12627]